Responses
Abstracts Accepted for Publication
Spondyloarthritis - treatment
AB0696 Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in auvergne (france)
Compose a Response to This Article
Other responses
No responses have been published for this article.